Performance of the Lumipulse plasma Aβ42/40 and pTau181 immunoassays in the detection of amyloid pathology.

Autor: Figdore, Daniel J., Wiste, Heather J., Bornhorst, Joshua A., Bateman, Randall J., Li, Yan, Graff‐Radford, Jonathan, Knopman, David S., Vemuri, Prashanthi, Lowe, Val J., Jr, Clifford R. Jack, Petersen, Ronald C., Algeciras‐Schimnich, Alicia
Předmět:
Zdroj: Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring; Jan2024, Vol. 16 Issue 1, p1-9, 9p
Abstrakt: INTRODUCTION: This study evaluated the performance of the Lumipulse plasma beta‐amyloid (Aβ) 42/40 and pTau181 compared to other assays to detect an abnormal amyloid‐positron emission tomography (PET). METHODS: Plasma samples from cognitively unimpaired (N = 179) and MCI/AD dementia (N = 36) individuals were retrospectively evaluated. Plasma Aβ42/40 and pTau181 were measured using the Lumipulse and Simoa immunoassays. An immunoprecipitation mass spectrometry (IP‐MS) assay for plasma Aβ42/40 was also evaluated. Amyloid‐PET status was the outcome measure. RESULTS: Lumipulse and IP‐MS Aβ42/40 exhibited the highest diagnostic accuracy for detecting an abnormal amyloid‐PET (areas under the curve [AUCs] of 0.81 and 0.84, respectively). The Lumipulse and Simoa pTau181 assays exhibited lower performance (AUCs of 0.74 and 0.72, respectively). The Simoa Aβ42/40 assay demonstrated the lowest diagnostic accuracy (AUC 0.57). Combining Aβ42/40 and pTau181 did not significantly improve performance over Aβ42/40 alone for Lumipulse (AUC 0.83) or over pTau181 alone for Simoa (AUC 0.71) DISCUSSION: The Lumipulse Aβ42/40 assay showed similar performance to the IP‐MS Aβ42/40 assay for detection of an abnormal amyloid‐PET; and both assays performed better than the two p‐tau181 immunoassays. The Simoa Aβ42/Aβ40 assay was the least accurate at predicting an abnormal amyloid‐PET status. Highlights: Lumipulse plasma Aβ42/Aβ40 AUC for abnormal amyloid‐PET detection was 0.81.This performance was comparable to previously reported IP‐MS and higher than Simoa.Performance of Alzheimer's disease blood biomarkers varies between assays. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz: